gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2024-34-1-37-46gastro-j-921Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL ARTICLESВлияние ресвератрола на функциональные пробы печени у пациентов с неалкогольной жировой болезнью печени: систематический обзор и метаанализ рандомизированных контролируемых исследованийEffects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trialshttps://orcid.org/0009-0007-5437-4402ЭбрагимпурП.EbrahimpourP.

Эбрахимпур Пардис — кафедра питания и пищевой гигиены Студенческого исследовательского комитета 

6517838636, Хамадан, просп. Шахида Фахмиде

Pardis Ebrahimpour — Department of Nutrition and Food Hygiene, Student Research Committee

6517838636, Hamadan, Shaheed Fahmideh Ave

Pardisebrpour@gmail.comhttps://orcid.org/0009-0005-8298-7121КарамянМ.KaramianM.

Карамян Мохаммад — кафедра питания и пищевой гигиены Студенческого исследовательского комитета 

6517838636, Хамадан, просп. Шахида Фахмиде

Mohammad Karamian — Department of Nutrition and Food Hygiene, Student Research Committee

6517838636, Hamadan, Shaheed Fahmideh Ave

mohamedkaramyan2000@gmail.comhttps://orcid.org/0000-0002-3164-0479ШарифиА.SharifiA.

Шарифи Амролла — кафедра питания и пищевой гигиены Студенческого исследовательского комитета 

6517838636, Хамадан, просп. Шахида Фахмиде

Amrollah Sharifi — Department of Nutrition and Food Hygiene, Nutrition Health Research Center

6517838636, Hamadan, Shaheed Fahmideh Ave

a.sharifi1983@gmail.comХамаданский университет медицинских наукИранHamadan University of Medical SciencesIslamic Republic of Iran2024150320243413746Copyright © Эбрагимпур П., Карамян М., Шарифи А., 20242024Эбрагимпур П., Карамян М., Шарифи А.Ebrahimpour P., Karamian M., Sharifi A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/921Актуальность

Актуальность. Некоторые исследования показали, что ресвератрол может предотвращать, задерживать или лечить повреждение печени.

Цель исследования

Цель исследования: предоставить современные данные о влиянии ресвератрола на ферменты печени (АЛТ и АСТ) у пациентов с НАЖБП. Для оценки влияния ресвератрола на ферменты печени у пациентов с НАЖБП был проведен систематический обзор и метаанализ путем поиска в различных базах данных опубликованных РКИ.

Материалы и методы

Материалы и методы. Систематический поиск в базах данных PubMed, Scopus и Web of Science проводился до сентября 2023 г. В данный систематический обзор и метаанализ вошли все РКИ, оценивающие влияние добавок ресвератрола на уровень АСТ и/или АЛТ в сыворотке крови у пациентов с НАЖБП. Эффект был представлен как средняя разница и 95 %-ный доверительный интервал (95 % ДИ) в модели случайных эффектов.

Результаты

Результаты. Были отобраны шесть отвечающих условиям поиска рандомизированных контролируемых исследований с участием 256 пациентов. Ресвератрол не оказывал существенного влияния на уровень концентрации сывороточной АЛТ (среднее значение = 3,30 МЕ/л; 95 % ДИ: –2,34–8,94; p = 0,25) и АСТ (среднее значение = 0,07 МЕ/л; 95 % ДИ: –2,96–3,10; p = 0,96). Более того, анализ подгрупп показал, что ни доза ресвератрола, ни продолжительность вмешательства не оказали существенного влияния на уровни АЛТ и АСТ в сыворотке.

Вывод

Вывод. Имеющиеся данные показывают, что прием ресвератрола не влияет на ферменты печени у пациентов с НАЖБП.

Background

Background. Some studies have shown that resveratrol may prevent, delay, or treat liver damage. This study aimed to provide up-to-date evidence regarding the effect of resveratrol on the liver enzymes (ALT & AST) in NAFLD patients. We conducted a systematic review and meta-analysis to evaluate the effect of resveratrol on liver enzymes in patients with NAFLD by searching various databases for published RCTs.

Methods

Methods. A systematic search in PubMed, Scopus, and Web of Science was performed up to September 2023. This systematic review and meta-analysis included all the RCT studies assessing resveratrol supplements on serum AST and/or ALT in NAFLD patients. The effect was presented as a mean difference and 95 % confidence interval (CI) in a random-effects model.

Results

Results. Finally, six eligible randomized controlled trials consisting of 256 patients were found. Resveratrol had no significant effect on serum ALT (Mean diff = 3.30 IU/L; 95 % CI: –2.34, 8.94; p = 0.25) and AST (Mean diff = 0.07 IU/L; 95 % CI: –2.96, 3.10; p = 0.96) concentrations. Moreover, subgroup analysis revealed that neither resveratrol dose nor intervention duration had any significant effect on the serum ALT and AST levels.

Conclusion

Conclusion. The current evidence shows that resveratrol supplementation did not affect liver enzymes in NAFLD patients.

ресвератролнеалкогольная жировая болезнь печениаланинаминотрансферазааспартатаминотрансферазаметаанализresveratrolnon-alcoholic fatty liver diseasealanine transaminaseaspartate aminotransferasesmeta-analysisReferencesDarand M., Farrokhzad A., Ghavami A., Hadi A., Karimi E., Fadel A., et al. Effects of resveratrol supplementation on liver enzymes: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021;75(3):e13692. DOI: 10.1111/ijcp.13692Darand M., Farrokhzad A., Ghavami A., Hadi A., Karimi E., Fadel A., et al. Effects of resveratrol supplementation on liver enzymes: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021;75(3):e13692. DOI: 10.1111/ijcp.13692Faghihzadeh F., Adibi P., Rafiei R., Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837–43. DOI: 10.1016/j.nutres.2014.09.005Faghihzadeh F., Adibi P., Rafiei R., Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837–43. DOI: 10.1016/j.nutres.2014.09.005Mojiri-Forushani H., Hemmati A., Khanzadeh A., Zahedi A. Effectiveness of grape seed extract in patients with nonalcoholic fatty liver: A randomized double-blind clinical study. Hepat Mon. 2022;22(1):e132309. DOI: 10.5812/hepatmon-132309Mojiri-Forushani H., Hemmati A., Khanzadeh A., Zahedi A. Effectiveness of grape seed extract in patients with nonalcoholic fatty liver: A randomized double-blind clinical study. Hepat Mon. 2022;22(1):e132309. DOI: 10.5812/hepatmon-132309Elgebaly A., Radwan I.A., AboElnas M.M., Ibrahim H.H., Eltoomy M.F., Atta A.A., et al. Resveratrol supplementation in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis. J Gastrointestin Liver Dis. 2017;26(1):59–67. DOI: 10.15403/jgld.2014.1121.261.elyElgebaly A., Radwan I.A., AboElnas M.M., Ibrahim H.H., Eltoomy M.F., Atta A.A., et al. Resveratrol supplementation in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis. J Gastrointestin Liver Dis. 2017;26(1):59–67. DOI: 10.15403/jgld.2014.1121.261.elyTeng M.L., Ng C.H., Huang D.Q., Chan K.E., Tan D.J., Lim W.H., et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32–42. DOI: 10.3350/cmh.2022.0365Teng M.L., Ng C.H., Huang D.Q., Chan K.E., Tan D.J., Lim W.H., et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32–42. DOI: 10.3350/cmh.2022.0365Wei S., Yu X. Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Complement Ther Med. 2021;57:102635. DOI: 10.1016/j.ctim.2020.102635Wei S., Yu X. Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Complement Ther Med. 2021;57:102635. DOI: 10.1016/j.ctim.2020.102635Faghihzadeh F., Adibi P., Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114(5):796–803. DOI: 10.1017/S0007114515002433Faghihzadeh F., Adibi P., Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114(5):796–803. DOI: 10.1017/S0007114515002433Kantartzis K., Fritsche L., Bombrich M., Machann J., Schick F., Staiger H., et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab. 2018;20(7):1793–7. DOI: 10.1111/dom.13268Kantartzis K., Fritsche L., Bombrich M., Machann J., Schick F., Staiger H., et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab. 2018;20(7):1793–7. DOI: 10.1111/dom.13268Teimouri M., Homayouni-Tabrizi M., Rajabian A., Amiri H., Hosseini H. Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2022;70:102863. DOI: 10.1016/j.ctim.2022.102863Teimouri M., Homayouni-Tabrizi M., Rajabian A., Amiri H., Hosseini H. Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2022;70:102863. DOI: 10.1016/j.ctim.2022.102863Dolinsky V.W., Dyck J.R. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta. 2011;1812(11):1477–89. DOI: 10.1016/j.bbadis.2011.06.010Dolinsky V.W., Dyck J.R. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta. 2011;1812(11):1477–89. DOI: 10.1016/j.bbadis.2011.06.010Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–42. DOI: 10.1038/nature05354Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–42. DOI: 10.1038/nature05354Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127(6):1109–22. DOI: 10.1016/j.cell.2006.11.013Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127(6):1109–22. DOI: 10.1016/j.cell.2006.11.013Chen S., Zhao X., Ran L., Wan J., Wang X., Qin Y., et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis. 2015;47(3):226–32. DOI: 10.1016/j.dld.2014.11.015Chen S., Zhao X., Ran L., Wan J., Wang X., Qin Y., et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis. 2015;47(3):226–32. DOI: 10.1016/j.dld.2014.11.015Mahmood W.A., Mshimesh B.A.R., Khazaal F.A.K., Jasim S.Y., Mahmood A.A. Potential effects of resveratrol on obesity-related nephropathy in Iraqi obese women. J Pharm Sci Res. 2018;10(5):999–1005.Mahmood W.A., Mshimesh B.A.R., Khazaal F.A.K., Jasim S.Y., Mahmood A.A. Potential effects of resveratrol on obesity-related nephropathy in Iraqi obese women. J Pharm Sci Res. 2018;10(5):999–1005.Asghari S., Asghari-Jafarabadi M., Somi M.H., Ghavami S.M., Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. J Am Coll Nutr. 2018;37(3):223– 33. DOI: 10.1080/07315724.2017.1392264Asghari S., Asghari-Jafarabadi M., Somi M.H., Ghavami S.M., Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. J Am Coll Nutr. 2018;37(3):223– 33. DOI: 10.1080/07315724.2017.1392264Heebøll S., Kreuzfeldt M., Hamilton-Dutoit S., Kjær Poulsen M., Stødkilde-Jørgensen H., Møller H.J., et al. Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51(4):456–64. DOI: 10.3109/00365521.2015.1107620Heebøll S., Kreuzfeldt M., Hamilton-Dutoit S., Kjær Poulsen M., Stødkilde-Jørgensen H., Møller H.J., et al. Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51(4):456–64. DOI: 10.3109/00365521.2015.1107620Chachay V.S., Macdonald G.A., Martin J.H., Whitehead J.P., O'Moore-Sullivan T.M., Lee P., et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092– 103.e1–6. DOI: 10.1016/j.cgh.2014.02.024Chachay V.S., Macdonald G.A., Martin J.H., Whitehead J.P., O'Moore-Sullivan T.M., Lee P., et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092– 103.e1–6. DOI: 10.1016/j.cgh.2014.02.024Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, 2019.Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, 2019.Wan X., Wang W., Liu J., Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. DOI: 10.1186/1471-2288-14-135Wan X., Wang W., Liu J., Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. DOI: 10.1186/1471-2288-14-135Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1–12. DOI: 10.1016/0197-2456(95)00134-4Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1–12. DOI: 10.1016/0197-2456(95)00134-4Farzin L., Asghari S., Rafraf M., Asghari-Jafarabadi M., Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res. 2020;90(3–4):279–89. DOI: 10.1024/0300-9831/a000528Farzin L., Asghari S., Rafraf M., Asghari-Jafarabadi M., Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res. 2020;90(3–4):279–89. DOI: 10.1024/0300-9831/a000528Soltani S., Sharifi-Zahabi E., Sangsefidi Z.S., Ahmadi Vasmehjani A., Meshkini F., Clayton Z.S., et al. The effect of resveratrol supplementation on biomarkers of liver health: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2023;37(3):1153–66. DOI: 10.1002/ptr.7719Soltani S., Sharifi-Zahabi E., Sangsefidi Z.S., Ahmadi Vasmehjani A., Meshkini F., Clayton Z.S., et al. The effect of resveratrol supplementation on biomarkers of liver health: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2023;37(3):1153–66. DOI: 10.1002/ptr.7719Akbari M., Tamtaji O.R., Lankarani K.B., Tabrizi R., Dadgostar E., Haghighat N., et al. The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2020;19(1):25. DOI: 10.1186/s12944-020-1198-xAkbari M., Tamtaji O.R., Lankarani K.B., Tabrizi R., Dadgostar E., Haghighat N., et al. The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2020;19(1):25. DOI: 10.1186/s12944-020-1198-x

The authors declare that there are no conflicts of interest present.